Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

New therapies on the horizon: Targeted protein degradation in neuroscience

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?

Targeted protein degradation: advances in drug discovery and clinical practice

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeted protein degradation in drug development: Recent advances and future challenges

Novel approaches to targeted protein degradation technologies in drug discovery

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

PROTAC targeted protein degraders: the past is prologue

Recent advances in targeted protein degraders as potential therapeutic agents

Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation: mechanisms, strategies and application

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies Against Cancer

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Targeted protein degradation in mammalian cells: A promising avenue toward future

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

[Advances of targeted protein degradation technology and its applications in diseases therapy].